AlphAIAlphAI — Financial news for AI agents
quiverquant.comOCT 72 min read$TWST

Twist Bioscience slides as insider sale filings and partnership skepticism pressure sentiment

Twist Bioscience (TWST) fell 6.8% due to insider sales and skepticism about its Lilly TuneLab partnership. The company reported record Q3 revenue of $118.4M and raised full-year guidance. CEO Emily Leproust sold 46,391 shares recently. Analysts' price targets range from $65 to $107.

Original reporting
quiverquant.com
Published Oct 7, 2026, 9:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 9:15 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Twist Bioscience slides as insider sale filings and partnership skepticism pressure sentiment — source image
Source · quiverquant.com
Decision brief

The 30-second read

$TWSTBearishLow
01

Why it matters

The combination of insider sell-offs and doubts about the Lilly TuneLab collaboration drove a 6.8% intraday decline.

02

Market read

Insider sales and sentiment shift are the primary catalysts for the stock's move.

03

What to watch

Recent $300M equity raise may dilute shares, offsetting some sell pressure.

Relevance 4/10Novelty 4/10Timing: today

Background

Twist Bioscience reported record Q3 revenue and raised guidance, but the stock fell on insider sale filings and partnership skepticism.

Company-level read

Ticker impact

$TWSTBearishHigh confidence
Context

Form 4 filing shows CEO and multiple insiders sold hundreds of thousands of shares, coinciding with a 6.8% drop in the stock.

Expected impact

likely continued downside pressure as market prices in the insider sell-off

Evidence & confidence

Large volume of insider sales across senior management and a sharp intraday decline suggest traders may short or reduce exposure.

Market effects

Sector

Biotech sector may see heightened scrutiny of insider activity, but no broader sector move.

Regional

Limited to US-listed biotech investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Insider sales could be routine tax-related transactions, not necessarily a bearish signal.

Key entities

  • Executive
    Emily Leproust

    CEO who sold 655 shares on Oct 1 and 45,736 shares on Oct 2.

  • Company
    Twist Bioscience

    Biotech firm experiencing share price pressure.

Read at source← All news

Related articles

OCT 8
$TWSTMed

Jefferies initiates Twist Bioscience stock at Hold on valuation

Jefferies initiated coverage on Twist Bioscience (TWST) with a Hold rating and $150 price target, citing premium valuation. The stock trades at $155.65 after a 391% YTD surge. Jefferies notes its market differentiation and AI-driven growth, but warns of high valuation expectations. TWST partners with Eli Lilly's TuneLab for AI/ML drug discovery, while BWS Financial rates it Sell, and Guggenheim reiterates Buy.

investing.com2 min
OCT 5
$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.

timothysykes.com3 min